


### AMENDMENTS TO THE CLAIMS

1. (Previously presented) A pharmaceutical composition containing at least one thiazolidin-4-one derivative of the Formula (I)



wherein:

R<sup>1</sup> represents a phenyl group independently mono-, di- or trisubstituted with lower alkyl, halogen, lower alkoxy, or -CF<sub>3</sub>;

R<sup>2</sup> represents lower alkyl; allyl; cyclopropyl; cyclobutyl; cyclopentyl; or mono- or di-lower alkylamino;

R<sup>3</sup> represents -O-CR<sup>7</sup>R<sup>8</sup>-CR<sup>9</sup>R<sup>10</sup>-(CR<sup>11</sup>R<sup>12</sup>)<sub>n</sub>-O-R<sup>13</sup>;

R<sup>4</sup> represents hydrogen; hydroxy; lower alkoxy; lower alkyl; or halogen;

R<sup>5</sup> and R<sup>6</sup> each represents independently lower alkyl;

R<sup>7</sup> represents hydrogen, lower alkyl, or hydroxymethyl;

R<sup>8</sup>, R<sup>9</sup>, R<sup>11</sup> and R<sup>12</sup> each represents independently hydrogen or methyl;

R<sup>10</sup> represents hydrogen or lower alkyl; in case n represents the integer 1, R<sup>10</sup> in addition represents lower alkoxy, hydroxy, -NH<sub>2</sub>, -NHR<sup>5</sup> or -NR<sup>5</sup>R<sup>6</sup>;

R<sup>13</sup> represents hydrogen; lower alkyl; hydroxycarbonyl-lower alkyl; 1-glyceryl or 2-glyceryl;

n represents the integer 0 or 1;

or configurational isomers, optically pure enantiomers, mixtures of enantiomers, enantiomeric racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, or a meso-form thereof, or pharmaceutically acceptable salts thereof, and inert carrier material.

2. (Previously presented) The pharmaceutical composition according to claim 1, in which said thiazolidin-4-one derivatives are (Z,Z)-isomers.


3-10. (Cancelled).

11. (Previously presented) The pharmaceutical composition of claim 1 further comprising one or more immunosuppressant compounds.

12. (Previously presented) The pharmaceutical composition according to claim 11, wherein said immunosuppressant compound is selected from the group consisting of cyclosporin, daclizumab, basiliximab, everolimus, tacrolimus (FK506), azathioprine, leflunomide, and 15-deoxyspergualin.

13-17. (Cancelled).

18. (Previously presented) Thiazolidin-4-one derivatives of the Formula (II)



Formula (II)

wherein:

R<sup>14</sup> represents a phenyl group mono-, di- or trisubstituted independently with lower alkyl, halogen, lower alkoxy, or -CF<sub>3</sub>;

R<sup>15</sup> represents lower alkyl; allyl; cyclopropyl; cyclobutyl; cyclopentyl; or mono- or di-lower alkylamino;

R<sup>16</sup> represents hydrogen; hydroxy; lower alkoxy; lower alkyl or halogen;

R<sup>17</sup> represents hydrogen, lower alkyl, or hydroxymethyl;

$R^{18}$ ,  $R^{19}$ ,  $R^{21}$  and  $R^{22}$  each represents independently hydrogen or methyl;  
 $R^{20}$  represents hydrogen or lower alkyl; and in case m represents the integer 1,  $R^{20}$  in addition represents lower alkoxy, hydroxy,  $-NH_2$ ,  $-NHR^5$  or  $-NR^5R^6$ ;  
 $R^{23}$  represents hydrogen; lower alkyl; hydroxycarbonyl-lower alkyl; 1-glyceryl or 2-glyceryl;  
m represents the integer 0 or 1;  
or configurational isomers, optically pure enantiomers, mixtures of enantiomers, enantiomeric racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, or a meso-form thereof, or pharmaceutically acceptable salts thereof.

19. (Original) Thiazolidin-4-one derivatives according to claim 18 in which said thiazolidin-4-one derivatives according to formula (II) are (Z,Z) isomers.

20. (Previously presented) Thiazolidin-4-one derivatives according to claim 18 or 19, wherein  $R^{14}$  represents a mono- or disubstituted phenyl group.

21. (Previously presented) Thiazolidin-4-one derivatives according to claim 18 or 19, wherein  $R^{14}$  represents a mono- or disubstituted phenyl group, substituted with methyl or halogen.

22. (Previously presented) Thiazolidin-4-one derivatives according to claim 18 or 19, wherein  $R^{15}$  represents lower alkyl.

23. (Previously presented) Thiazolidin-4-one derivatives according to claim 18 or 19, wherein  $R^{16}$  represents halogen or methyl.

24. (Previously presented) Thiazolidin-4-one derivatives according to claim 18 or 19, wherein m represents the integer 0, and  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$  and  $R^{20}$  represent hydrogen.

25. (Previously presented) Thiazolidin-4-one derivatives according to claim 18 or 19, wherein  $m$  represents the integer 1,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{21}$  and  $R^{22}$ , represent hydrogen, and  $R^{20}$  represents hydroxy.

26. (Previously presented) Thiazolidin-4-one derivatives according to claim 18 or 19, wherein  $R^{23}$  represents hydrogen.

27. (Previously presented) Thiazolidin-4-one derivatives according to claim 18 or 19, wherein  $m$  represents the integer 0,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$  and  $R^{23}$  represent hydrogen.

28. (Previously presented) Thiazolidin-4-one derivatives according to claim 18 or 19, wherein  $m$  represents the integer 1,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{21}$ ,  $R^{22}$  and  $R^{23}$  represent hydrogen, and  $R^{20}$  represents hydroxy.

29. (Previously presented) Thiazolidin-4-one derivatives according to claim 18 or 19, wherein  $R^{14}$  represents a mono- or disubstituted phenyl group, substituted with methyl or halogen, and  $R^{15}$  represents lower alkyl.

30. (Previously presented) Thiazolidin-4-one derivatives according to claim 18 or 19, wherein  $R^{14}$  represents a mono- or disubstituted phenyl group, substituted with methyl or halogen,  $m$  represents the integer 0, and  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$  and  $R^{23}$  represent hydrogen.

31. (Previously presented) Thiazolidin-4-one derivatives according to claim 18 or 19, wherein  $R^{14}$  represents a mono- or disubstituted phenyl group, substituted with methyl or halogen,  $m$  represents the integer 1,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{21}$ ,  $R^{22}$  and  $R^{23}$  represent hydrogen, and  $R^{20}$  represents hydroxy.

32. (Previously presented) Thiazolidin-4-one derivatives according to claim 18 or 19, wherein  $R^{14}$  represents a mono- or disubstituted phenyl group, substituted with

methyl or halogen, and R<sup>15</sup> represents lower alkyl, R<sup>16</sup> represents methyl or halogen, m represents the integer 0, and R<sup>17</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>20</sup> and R<sup>23</sup> each represent hydrogen.

33. (Previously presented) Thiazolidin-4-one derivatives according to claim 18 or 19, wherein R<sup>14</sup> represents a mono- or disubstituted phenyl group, substituted with methyl or halogen; and R<sup>15</sup> represents lower alkyl, R<sup>16</sup> represents methyl or halogen, m represents the integer 1, R<sup>17</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>21</sup>, R<sup>22</sup>, R<sup>23</sup> represent hydrogen, and R<sup>20</sup> represents hydroxy.

34. (Currently amended) A thiazolidin-4-one derivative according to claim 18 selected from the group consisting of:

5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-3-o-tolyl-thiazolidin-4-one,

5-[4-[2-(2,3-dihydroxy-propoxy)-ethoxy]-benz[Z]ylidene]-2-([Z]-isopropylimino)-3-o-tolyl-thiazolidin-4-one,

5-[3-chloro-4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-3-o-tolyl-thiazolidin-4-one,

5-[3-chloro-4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-3-o-tolyl-thiazolidin-4-one,

5-[4-(2-hydroxy-ethoxy)-3-methoxy-benz[Z]ylidene]-2-([Z]-isopropylimino)-3-o-tolyl-thiazolidin-4-one,

5-[4-(3-hydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-3-o-tolyl-thiazolidin-4-one,

5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-3-o-tolyl-thiazolidin-4-one,

5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-3-m-tolyl-thiazolidin-4-one,

5-[3-chloro-4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-3-m-tolyl-thiazolidin-4-one,

5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-3-m-tolyl-thiazolidin-4-one,

5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-3-p-tolyl-thiazolidin-4-one,

5-[3-chloro-4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-3-p-tolyl-thiazolidin-4-one,

5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-3-p-tolyl-thiazolidin-4-one,

3-(2,3-dimethyl-phenyl)-5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-thiazolidin-4-one,

5-[4-[2-(2,3-dihydroxy-propoxy)-ethoxy]-benz[Z]ylidene]-3-(2,3-dimethyl-phenyl)-2-([Z]-isopropylimino)-thiazolidin-4-one,

5-[3-chloro-4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-3-(2,3-dimethyl-phenyl)-2-([Z]-isopropylimino)-thiazolidin-4-one,

3-(2,3-dimethyl-phenyl)-5-[3-fluoro-4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-thiazolidin-4-one,

3-(2,3-dimethyl-phenyl)-5-[4-(2-hydroxy-ethoxy)-3-methyl-benz[Z]ylidene]-2-([Z]-isopropylimino)-thiazolidin-4-one,

3-(2,3-dimethyl-phenyl)-5-[4-(2-hydroxy-ethoxy)-3-methoxy-benz[Z]ylidene]-2-([Z]-isopropylimino)-thiazolidin-4-one,

5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-3-(2,3-dimethyl-phenyl)-2-([Z]-isopropylimino)-thiazolidin-4-one,

3-(2,4-dimethyl-phenyl)-5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-thiazolidin-4-one,

**5-(2,3-dihydro-benzo[1,4]dioxin-6-[Z]-ylmethylene)-3-(2,6-dimethyl-phenyl)-2-([Z]-isopropylimino)-thiazolidin-4-one,**

3-(2,6-dimethyl-phenyl)-5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-thiazolidin-4-one,

3-(2-chloro-phenyl)-5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-thiazolidin-4-one,

5-[3-chloro-4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-3-(2-chloro-phenyl)-2-([Z]-isopropylimino)-thiazolidin-4-one,

5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-3-(2-chloro-phenyl)-2-([Z]-isopropylimino)-thiazolidin-4-one,

5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-3-(2-methoxy-phenyl)-thiazolidin-4-one,

5-[3-chloro-4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-3-(2-methoxy-phenyl)-thiazolidin-4-one,

**5-(2,3-dihydro-benzo[1,4]dioxin-6-[Z]-ylmethylene)-2-([Z]-isopropylimino)-3-methoxy-phenyl)-thiazolidin-4-one,**

5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-3-(4-methoxy-phenyl)-thiazolidin-4-one,

5-[3-chloro-4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-3-(4-methoxy-phenyl)-thiazolidin-4-one,

5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one,

5-[4-(3-hydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one,

5-[3-chloro-4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one,

5-[4-(2-hydroxy-ethoxy)-3-methyl-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one,

5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one,

(R)- 5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one,

(S)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one,

3-(2,3-dimethyl-phenyl)-5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-thiazolidin-4-one,

5-[4-[2-(2,3-dihydroxy-propoxy)-ethoxy]-benz[Z]ylidene]-3-(2,3-dimethyl-phenyl)-2-([Z]-propylimino)-thiazolidin-4-one,

5-[3-chloro-4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-3-(2,3-dimethyl-phenyl)-2-([Z]-propylimino)-thiazolidin-4-one,

3-(2,3-dimethyl-phenyl)-5-[4-(2-hydroxy-ethoxy)-3-methyl-benz[Z]ylidene]-2-([Z]-propylimino)-thiazolidin-4-one,

3-(2,3-dimethyl-phenyl)-5-[4-(2-hydroxy-ethoxy)-3-methoxy-benz[Z]ylidene]-2-([Z]-propylimino)-thiazolidin-4-one,

5-[4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-3-(2,3-dimethyl-phenyl)-2-([Z]-propylimino)-thiazolidin-4-one,

5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-3-(2,3-dimethyl-phenyl)-2-([Z]-propylimino)-thiazolidin-4-one,

2-([Z]-ethylimino)-5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-3-o-tolyl-thiazolidin-4-one,

5-[3-chloro-4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-ethylimino)-3-o-tolyl-thiazolidin-4-one,

3-(2,3-dimethyl-phenyl)-2-([Z]-ethylimino)-5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-thiazolidin-4-one,

5-[3-chloro-4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-3-(2,3-dimethyl-phenyl)-2-([Z]-ethylimino)-thiazolidin-4-one,

2-([Z]-butylimino)-5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-3-o-tolyl-thiazolidin-4-one,

2-([Z]-butylimino)-5-[3-chloro-4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-3-o-tolyl-thiazolidin-4-one,



2-([Z]-butylimino)-3-(2,3-dimethyl-phenyl)-5-[4-(2-hydroxy-ethoxy)-  
benz[Z]ylidene]-thiazolidin-4-one,

2-([Z]-butylimino)-5-[3-chloro-4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-3-(2,3-  
dimethyl-phenyl)-thiazolidin-4-one, and

5-[3-chloro-4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-3-(2,3-dimethyl-phenyl)-2-  
([Z]-methylimino)-thiazolidin-4-one.

35. (Previously presented) A thiazolidin-4-one derivative according to claim  
18 selected from the group consisting of:

5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-  
3-o-tolyl-thiazolidin-4-one,

5-[3-chloro-4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-3-(2,3-dimethyl-phenyl)-2-  
([Z]-isopropylimino)-thiazolidin-4-one,

5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-3-(2,3-dimethyl-  
phenyl)-2-([Z]-isopropylimino)-thiazolidin-4-one,

5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-  
o-tolyl-thiazolidin-4-one,

(R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-  
3-o-tolyl-thiazolidin-4-one,

(S)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-  
3-o-tolyl-thiazolidin-4-one,

5-[3-chloro-4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-3-(2,3-dimethyl-phenyl)-2-  
([Z]-propylimino)-thiazolidin-4-one,

5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-3-(2,3-dimethyl-  
phenyl)-2-([Z]-propylimino)-thiazolidin-4-one, and

5-[3-chloro-4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-3-(2,3-dimethyl-phenyl)-2-  
([Z]-ethylimino)-thiazolidin-4-one.

36-39. (Cancelled).

40. (Previously presented) A pharmaceutical composition comprising at least one thiazolidin-4-one derivative of claim 18 and inert carrier material.

41-44. (Cancelled).

45. (Previously presented) A process for the preparation of a pharmaceutical composition comprising mixing one or more thiazolidin-4-one derivatives of any one of claim 18, 34 or 35 with inert excipients.

46. (Previously presented) A process for the preparation of the pharmaceutical composition of claim 1, comprising mixing one or more thiazolidin-4-one derivatives according to Formula (I) with inert excipients.

47-56. (Cancelled).

57. (Previously presented) The compound, (R)- 5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one.

58. (Previously presented) A pharmaceutical composition comprising the compound of claim 57 and inert carrier material.